Panacea Life Sciences Holdings, Inc. Capital Expenditures Incurred but Not yet Paid
Panacea Life Sciences Holdings, Inc. (PLSH) reported Capital Expenditures Incurred but Not yet Paid of $261.90 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-04-01
- Panacea Life Sciences Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $41.60K, a 81.12% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $51.72K.
- Panacea Life Sciences Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $66.23K.
- Panacea Life Sciences Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $102.34K, a 14.83% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $261.90K, a 53.59% decline from fiscal 2021.
- Panacea Life Sciences Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $564.37K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-12-31 | $41.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $93.32K derived: sum of 2 quarters · filed 2024-04-01 | $159.56K derived: sum of 3 quarters · filed 2024-04-01 | $261.90K 10-K · filed 2024-04-01 |
| 2022-09-30 | $51.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $117.95K derived: sum of 2 quarters · filed 2023-11-14 | $220.30K 10-Q · filed 2023-11-14 | $440.69K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $66.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-15 | $168.58K 10-Q · filed 2023-08-15 | $388.97K derived: sum of 3 quarters · filed 2023-08-15 | |
| 2022-03-31 | $102.34K 10-Q · filed 2023-05-12 | $322.73K derived: sum of 2 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $220.39K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $564.37K 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $343.98K 10-Q · filed 2022-11-14 | |||
| 2021-03-31 | $120.17K 10-Q · filed 2022-05-13 |